Jason Karp‘s Tourbillon Capital Partners has retaken a stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) after having sold off its previous position in the stock during the second quarter. A new 13G filing with the SEC shows that Tourbillon has amassed a position of just over 3.33 million shares, or 6.2% of the outstanding shares. Tourbillon owned over 805,000 shares of the company at the end of March, but sold out of that position during the second quarter. While it appears that the fund missed out on the recent run-up in the stock, it was not going to miss out on taking advantage of the recent pullback. Sarepta shares have gained 115% since the end of June, but have lost 34% since October 6.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares more than doubled in mid-September after the FDA granted accelerated approval for its Duchenne’s treatment Exondys 51 (eteplirsen). The acceptance of the treatment, which didn’t appear to be any more effective than BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s rejected DMD candidate (which the company halted development on afterwards), came as a surprise to many, and has caused a good deal of controversy. PTC Therapeutics, Inc. (NASDAQ:PTCT) shares were hammered earlier this month after its own DMD treatment was also rejected (again) by the FDA.
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have fallen off in recent weeks after the company revealed that reimbursement takes 30-90 days, which caused some analysts to cut their near-term sales forecasts for the drug. However, multiple analysts have called the recent selling overdone, and have price targets on the stock that suggest 50%+ upside potential.
Sarepta Therapeutics Inc (NASDAQ:SRPT) was held in the portfolios of 20 of the hedge funds in our database at the end of June, up by one quarter-over-quarter. Those investors owned $309 million worth of the company’s shares, and included Joseph Edelman’s Perceptive Advisors (3.77 million shares), Steve Cohen’s Point72 Asset Management (2.75 million shares), and Hal Mintz’s Sabby Capital (783,497 shares).
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Tourbillon Capital Partners | 0 | 3,332,300 | 0 | 3,332,300 | 3,332,300 | 6.2% |
| Jason H. Karp | 0 | 3,332,300 | 0 | 3,332,300 | 3,332,300 | 6.2% |
Page 1 of 8 – SEC Filing
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Zebra Capital Management is Fond of These Financial Stocks
Tim Curro’s Value Holdings Bets on Services Sector
Hedge Fund Highlights: David Einhorn, Tom Steyer & Dan Loeb
Millennium Management’s Subsidiary Blue Arrow Capital Loves These Stocks...
Keypoint Capital Management Bets Big on Financial Stocks
Hedge Fund News: Marc Lasry, Seth Klarman & Jonathan Savitz
